Potential Relationship Between $eGFR_{\text{cystatin C}}/eGFR_{\text{creatinine}}$ -ratio and Glomerular Basement Membrane Thickness in Diabetic Kidney Disease

Carl M. Öberg M.D., Ph.D.¹, Martin Lindström M.D.², Anders Grubb M.D., Ph.D.³, and
Anders Christensson M.D., Ph.D.⁴

¹ Department of Clinical Sciences Lund, Lund University, Department of Nephrology, Skåne University Hospital, Lund, Sweden

² Department of Laboratory Medicine Malmö, Lund University, Center for Molecular Pathology, Skåne University Hospital, Malmö, Sweden

³ Department of Laboratory Medicine, Lund University, Department of Clinical Chemistry, Skåne University Hospital, Lund, Sweden

⁴ Department of Clinical Sciences Malmö, Lund University, Skåne University Hospital, Department of Nephrology, Malmö, Sweden

Running title: Reduced cystatin C $eGFR$ in DKD

Abstract: 243 words

Word count main text 3168 (excl. methods, supplement, refs)

Correspondance: Carl M. Öberg, Dept. of Nephrology, Alwall House, Skane Univ. Hospital (SUS) Lund, Barngatan 2, 221 85, Lund, SWEDEN. Phone: +46-46-17 26 62 E-mail:

carl.oberg@med.lu.se

Keywords: diabetic kidney disease; estimated GFR; two-pore model; glomerular barrier thickness; ratio $eGFR_{\text{cystatin C}}/eGFR_{\text{creatinine}}$

Significance statement

Increased thickness of the glomerular basement membrane (GBM) is an early structural abnormality in diabetes, and has been identified as an independent risk factor for progression to diabetic nephropathy (DN). Increased GBM thickness will increase the diffusion length of mid-sized molecules like cystatin C across the renal filter, potentially leading to increased plasma concentrations and lower estimated GFR from cystatin C. The authors show theoretically that estimated GFR from cystatin C ($eGFR_{\text{cystatin C}}$) is lower than that of creatinine ($eGFR_{\text{creatinine}}$) in DN to a degree directly depending on GBM thickness. In line with theory, they provide clinical data showing a lower $eGFR_{\text{cystatin C}}$ in diabetic patients with the $eGFR_{\text{cystatin C}}/eGFR_{\text{creatinine}}$ -ratio being inversely correlated to GBM thickness assessed from electron micrographs.

ABSTRACT

Background Diabetic nephropathy (DN) is a leading cause of end stage renal disease and renal replacement therapy worldwide. A pathophysiological hallmark of DN is glomerular basal membrane (GBM) thickening, whereas this feature is absent in minimal change disease. Theoretically, a thicker GBM will impede the diffusion of middle-molecules such as cystatin C, potentially leading to a lower estimated GFR (eGFR) from cystatin C compared to that of creatinine. Here we test the hypothesis that thickening of the glomerular filter leads to an increased diffusion length, and lower clearance, of cystatin C.

Methods Twenty-nine patients with a kidney biopsy diagnosis of either DN (n=17) or minimal change disease (MCD) (n=12) were retrospectively included in the study. GBM thickness was measured at 20 separate locations in the biopsy specimen and plasma levels of cystatin C and creatinine were retrieved from health records. A modified two-pore model was used to simulate the effects of a thicker GBM on glomerular water and solute transport.

Results The mean age of the patients was 52 years, and 38% were women. The mean $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ -ratio was 74% in DKD compared to 98% in MCD ($P < 0.001$). Average GBM thickness was strongly inversely correlated to the $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ -ratio (Pearson's $r = -0.61$, $P < 0.01$). Two-pore modeling predicted a $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ -ratio of 78% in DN.

Conclusions We provide clinical and theoretical evidence suggesting that thickening of the glomerular filter, increasing the diffusion length of cystatin C, lowers the $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ -ratio in DN.

Introduction

The number of patients with diabetes and chronic kidney disease (CKD) is rapidly increasing worldwide ¹. Advanced diabetic kidney disease is considered an irrecoverable condition, and identifying diagnostic methods and applying early interventions are crucial to reduce the global burden of end stage renal disease.

Cystatin C has emerged as a marker for noninvasive estimation of GFR ² ever since it was noted that its reciprocal concentration correlated closely with GFR ³. Compared to creatinine, it appears to be especially well suited for the detection of early impairments in renal function ^{4, 5}. Cystatin C has a rather high molecular weight (Mw) of 13.3 kDa and a Stokes-Einstein radius of ~1.8 nm compared to that of smaller endogenous markers such as creatinine (MW 0.1 kDa and SE-radius 0.3 nm). Nonetheless, cystatin C is regarded as a better predictor of adverse outcomes ^{6, 7} as well as a better marker for GFR in combination with creatinine ^{8, 9} compared to creatinine alone.

The glomerular clearance of a small molecule like creatinine should very closely match that of the permeate flux (i.e. the glomerular filtration rate) over the glomerular filtration barrier (GFB) whereas the clearance of larger molecules will be increasingly dependent on the size of the selective elements in the GFB (i.e. the functional small pore radius). In fact, while most of the plasma content of cystatin C and other small plasma proteins are catabolized in the renal tubules ¹⁰, cystatin C is not freely filtered across the GFB (sieving coefficient 0.84). Being a middle-sized molecule it likely has a glomerular fractional clearance similar to that of β_2 -microglobulin ¹¹ and other small plasma proteins ³ (or 26 Å dextran ¹²).

Shrunken pore syndrome (SPS) is defined as a difference in estimated GFR from cystatin C vs. creatinine ($\text{eGFR}_{\text{Cystatin C}} < 60\% \text{eGFR}_{\text{Creatinine}}$ in the absence of non-renal

influence on the levels of cystatin C or creatinine¹³), and has been identified as a strong independent risk factor for mortality in patients undergoing elective coronary artery bypass grafting⁹ and chronic kidney disease. This effect was seen also regardless of eGFR level¹⁴. The suggested mechanism for SPS is a shrinking of the glomerular pore size leading to an increased plasma concentration of small plasma proteins like cystatin C, β_2 -microglobulin, beta-trace protein and retinol binding protein^{13, 15}. Small plasma proteins like cystatin C are cleared from the body by glomerular filtration and degraded by renal tubular catabolism whereas only smaller part of large proteins are cleared in the kidneys^{16, 17}. Thus, when the glomerular filtration rate is decreased due to renal disease, plasma concentrations of small plasma solutes will increase¹⁵ which is the basis of noninvasive GFR estimation.

A decreased pore size is not the only possible mechanism leading to SPS and/or reduced estimated GFR from cystatin C vs. creatinine, but could potentially result also from a thicker glomerular barrier leading to an increased diffusion length for middle molecules like cystatin C. One of the earliest structural alterations in diabetic kidney disease (DKD), preceding microproteinuria, is thickening of the GBM¹⁸ whereas this condition is absent in minimal change disease (MCD). The aim of the current study was to test the hypothesis that estimated GFR from cystatin C is lower compared to that of creatinine in DKD vs. MCD, and that this difference is correlated to GBM thickness. To explore if the observed alterations can be explained theoretically, we used the heteroporous two-pore model by Deen and colleagues¹⁹ adapted to human physiological conditions. Due to the limited experimental information available on the hemodynamic conditions in the human glomerulus, some physiological parameters had to be estimated based on previous modeling by Oken²⁰ and Navar *et al*²¹.

Methods

Design, Setting, and Participants

All patients referred for a kidney biopsy in Skåne, southern part of Sweden, are registered in a local data repository called the *Örestadsregistret* (*Örestad Registry*). We assessed 579 entries in the Örestad Registry between August 2013 and August 2017. Inclusion criteria were biopsy diagnosis of diabetic kidney disease or minimal change disease and estimated GFR measurement using both cystatin C and creatinine within 2 weeks of the time of biopsy. All patients were assessed for medication including angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers and corticosteroids. Exclusion criteria were signs of other pathologies in the biopsy specimen, e.g. Ig A nephropathy or hypertensive nephrosclerosis. We identified 12 patients with minimal change disease and 17 patients with DKD who fulfilled the inclusion criteria and none of the exclusion criteria. The Research Ethics Board at Lund University approved the study (Dnr 2017/568). Patient data and samples were treated anonymously in all statistical analyses. This study is in accordance with the recommendations outlined in the "STAndards for the Reporting of Diagnostic accuracy studies" (STARD) statement ²² (Supplemental File 1).

Laboratory measurements for renal function

Plasma concentrations of creatinine and cystatin C were collected from health records. Cystatin C was determined by a particle-enhanced immunoturbidimetric method using a reference material traceable to the international cystatin C calibrator ²³. Creatinine was determined by an enzymatic colorimetric assay using a calibrator traceable to primary reference material with values assigned by isotope dilution mass spectrometry ²⁴. GFR was

estimated (eGFR) from the LMrev formula based on creatinine ²⁴ and the CAPA formula based on cystatin C ²³.

A modified two-pore model to simulate the effects of a thicker GBM on glomerular water and solute transport

Three pathophysiological changes will affect glomerular solute and water transport in DKD:

1. GBM hypertrophy, 2. glomerular hypertension and 3. hyperfiltration (single nephron). We simulated these changes by 1. lowering the filtration coefficient (L_pA) and solute diffusion capacity (half for twice the thickness and so on), 2. increasing the glomerular hydraulic pressure gradient to achieve 3. a single nephron GFR (SNGFR) of 90 nl/min. If the glomerular filtration coefficient, hydraulic pressure gradient, single nephron GFR, and (afferent) oncotic pressure are known, then the single nephron plasma flow profile $Q(y)$ and the plasma protein concentration $C_{pr}(y)$ as functions of the relative position y (position/total length) along the glomerular capillary, can be determined by use of the conservation of mass equations

$$C_{pr}(0)Q(0) = C_{pr}(y)Q(y) \quad (1)$$

$$\frac{dQ(y)}{dy} = -J_v(y) \quad (2)$$

Re-arranging these equations gives the well-known ^{19, 25, 26} non-linear ordinary differential equation

$$\frac{dC_{pr}}{dy} = \frac{C_{pr}^2}{C_{pr}(0)Q(0)} J_v(y) \quad (3)$$

Above, $J_v(y)$ is the local filtration flux ²⁶ which is equal to the local Starling pressure (difference between hydraulic and oncotic pressure gradients) multiplied by the ultrafiltration coefficient (L_pA)

$$J_v(y) = L_p A \left((P_{GC} - P_{BS} - P_{drop}(y)) - (\Pi_{GC}(y) - \Pi_{BS}) \right) \quad (4)$$

The colloid osmotic pressure in the glomerular capillary (Π_{GC}) was calculated using the Landis-Pappenheimer equation, ($\Pi = 2.1C_{pr} + 0.16C_{pr}^2 + 0.009C_{pr}^3$), assuming a total plasma protein concentration of 6.7 g/dL corresponding to a plasma colloid osmotic pressure of ~24 mmHg. In the human glomerulus, the capsular hydrostatic pressure (P_{BS}) has been estimated to be between 15-20 mmHg^{20, 21} and the capsular oncotic pressure (Π_{BS}) 0 mmHg. In order to achieve an effective filtration pressure (EFP) in the normal state of ~10 mmHg, we assumed a glomerular hydraulic pressure gradient of 40 mmHg (cf.²¹ and²⁰), implying a glomerular capillary pressure (P_{GC}) of 55-60 mmHg. The pressure drop along the glomerular capillary network was set to 1 mmHg¹⁹. The renal plasma flow (RPF or $Q(o)$) was determined with the gradient descent algorithm described in²⁵.

Actual measurements of glomerular sieving coefficients for small proteins like cystatin C across the human glomerular filter are scarce in the literature. Perhaps the most reliable estimations are those obtained in children with Fanconi syndrome^{17, 27}, although these sieving coefficients may be slightly low due to residual tubular reabsorption²⁷. Based on the sieving data in¹⁷ and previous results from the rat glomerular filtration barrier we assumed a small pore radius (r_s) of 3.7 nm and a large pore radius (r_L) of 11.0 nm (cf.¹¹). Again, if assuming conservation of mass (see also²⁵), the change in solute (protein) concentration $C_i(y)$ due to glomerular filtration (at position y along the glomerular capillary) is given by

$$\frac{dC_i}{dy} = - \frac{J_s(y) - J_v(y)C_i}{Q(y)} \quad (5)$$

where the local solute flux of a solute, $J_s(y)$, is calculated from

$$J_s(y) = f_s J_v(y) \frac{C_i(y)W_s}{1 - (1 - W_s)e^{-Pe_s}} + f_L J_v(y) \frac{C_i(y)W_L}{1 - (1 - W_L)e^{-Pe_L}} \quad (6)$$

where $C_i(y)$ is the solute concentration at position y along the glomerular capillary; f_S and f_L are the fractional volume flows; W_S and W_L are the convective hindrance factors²⁸, across the small- and the large pores respectively. Péclet numbers (Pe_S and Pe_L) are calculated from

$$Pe_S = f_S J_v(y) \frac{W_S}{PS_S} \quad (7)$$

$$Pe_L = f_L J_v(y) \frac{W_L}{PS_L} \quad (8)$$

Solute diffusion capacities PS_S and PS_L (cf. eqn 8 and 9 in²⁹) were calculated from

$$PS_S = H_S D \cdot \alpha_S L_p A \frac{8\eta}{r_S^2} \quad (9)$$

$$PS_L = H_L D \cdot \alpha_L L_p A \frac{8\eta}{r_S^2} \quad (10)$$

where H_S and H_L are the diffusive hindrance factors²⁸, D is the free diffusion coefficient calculated from the Stokes-Einstein radius of the solute protein, η is the viscosity of the permeate (0.7 mPa·s), α_S and α_L denote the fractional hydraulic conductance of the small and large pore system, respectively (for a discussion on the differences between $\alpha_{S/L}$ and $f_{S/L}$ and their calculation, see³⁰). In the current article the f_L parameter was set to $\sim 1 \cdot 10^{-4}$ (similar to that obtained in humans using Ficoll³¹) which gives a α_L of $\sim 3 \cdot 10^{-5}$. We assumed a steady state plasma clearance of cystatin C (and creatinine), occurring chiefly via glomerular filtration:

$$Cl_{cysC} = GFR \cdot \theta_{cysC} \quad (11)$$

where θ_{cysC} is the glomerular sieving coefficient of cystatin C. A small pore system with a 3.7 nm pore radius implies a sieving coefficient for cystatin C of ~ 0.87 . For an adult male having a GFR of 120 mL/min, this translates to a cystatin C concentration of about 0.69 mg/L.

Measurement of glomerular basal membrane (GBM)

Core biopsies were first put in 4% formaldehyde and thereafter embedded in paraffin. Cases were sectioned in two levels, each 1,5 μ m thick, and stained for HE, ABPAS, TRI, EVG, PASM and AK and each case were re-evaluated by light microscopy. Samples for electron microscopy (EM) were put in 4% formaldehyde and embedded in (plastic) and thereafter sectioned in 60 nm thick sections. Transmission electron microscopy was performed for each case with a transmission microscope (TECNAI FEJ Company) as well as photo documented in JPEG-format by a digital camera (VELETA). One glomerulus per case with at least one full segment was examined with electron microscopy. Each case was evaluated regarding basal membranes, foot processes and mesangium and were found to correspond to the diagnosis of diabetic nephropathy or minimal change nephropathy. Each case showed homogenous thickness of basal membranes of segments without any focal irregularities or deposits. For each glomeruli 20 measurements points were taken in a representative loop. GBM thickness was assessed through ultrastructural morphometry on enlarged electron micrographs as the arithmetic mean of 20 orthogonal intercepts across the GBM. Electron micrographs were available in 8 patients with MCD and in 11 patients with DKD.

Statistical methods

Values are presented as average (IQR) unless otherwise specified. Differences between groups were assessed using a Wilcoxon signed rank test. Monte Carlo based power analysis (10,000 simulations) was conducted, applying Wilcoxon tests between fixed unequal sample sizes of 17 and 12 patients, showing that the study had 89% power to detect a true difference of 0.2 in $eGFR_{cystatin\ C}/eGFR_{creatinine}$ -ratio assuming a SD of 0.16 (Cohen's $d = 1.25$). Moreover, a sample size of 19 patients had 87% power to detect a true correlation

coefficient of 0.6 or better between GBM-thickness and $eGFR_{\text{cystatin C}}/eGFR_{\text{creatinine}}$ -ratio, at a significance level of 0.05. A post-hoc ANCOVA was applied using the model [ratio ~ eGFR + diagnosis] using type III SS. We assumed an α -level of 0.05 and a β -level of 0.20 unless otherwise specified. P-values are denoted: * for $P < 0.05$, ** for $P < 0.01$ and *** for $P > 0.001$. All statistical calculations were performed using R for macOS (R Foundation for Statistical Computing, version 3.5.1)

Results

Reduced Ratio of $eGFR_{cystatin\ C}/eGFR_{creatinine}$ in Diabetic Kidney Disease vs. Minimal Change Disease

We first assessed estimated GFR (eGFR) from cystatin C and creatinine in two groups of patients with a biopsy diagnosis of either diabetic kidney disease (DKD) (n=17) or minimal change disease (MCD) (n=12). Baseline characteristics and eGFR estimations are shown in Table 1. Median age of the patients was 52 (41-64) years at the time of biopsy with no difference between the groups, and 38% were female. Plotted in Figure 1 A is the ratio $eGFR_{cystatin\ C}/eGFR_{creatinine}$ which was lower ($p=0.0004$, $W=26$) in DKD patients compared with MCD patients. Furthermore, 4 patients with DKD also fulfilled the criteria for shrunken pore syndrome, defined as $eGFR_{cystatin\ C} < 60\% eGFR_{creatinine}$ whereas none of the MCD patients fulfilled this criteria (the lowest ratio in the MCD group was ~76%). Average estimated GFR (eGFR), calculated as the arithmetic average of $eGFR_{cystatin\ C}$ and $eGFR_{creatinine}$, was different in the groups, which is expected since GFR is usually much less affected in MCD (Table 1). To investigate if reduced eGFR was in itself correlated to a reduced ratio, we performed a *post-hoc* analysis of co-variance showing no significant main effect of eGFR on the $eGFR_{cystatin\ C}/eGFR_{creatinine}$ -ratio ($F_{1,26}=0.2$, $p=0.65$).

The $eGFR_{cystatin\ C}/eGFR_{creatinine}$ -ratio is strongly correlated to GBM thickness

Linear regression was performed to investigate the theoretically predicted relationship between the $eGFR_{cystatin\ C}/eGFR_{creatinine}$ -ratio and GBM thickness (nm). The scatterplot (Figure 2) indeed suggested a negative linear relationship between the two, which was confirmed with a Pearson's correlation coefficient of -0.61. Simple linear regression showed a significant relationship between $eGFR_{cystatin\ C}/eGFR_{creatinine}$ -ratio and GBM thickness (nm)

($p < 0.01$). The slope coefficient for mean GBM-thickness was $-0.04\% \text{ nm}^{-1}$ so the $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ -ratio was apparently reduced by $\sim 4\%$ for every 100 nm increased thickness. As shown in Figure 2 B, the plot of residuals vs. the independent parameter indicated that the residuals were approximately normally distributed. To explore whether body composition and muscle mass affect the ratio $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ we used linear correlation between weight vs $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ -ratio and body mass index (BMI) vs $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ -ratio, but found no significant association.

Reduced Ratio of $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ is theoretically dependent on GBM thickness

Pathophysiological hallmarks in the development of diabetic glomerulosclerosis are glomerular hypertrophy, hypertension and hyperfiltration; processes that were here modeled *in silico* by increasing the thickness of the GBM and the effective filtration pressure to result in a SNGFR of 90 nL min^{-1} . We first increased glomerular pressure linearly with decreasing GFB conductance (+10 mmHg for twice the thickness, +20 mmHg for triple and so on). This had the effect of reducing the $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ ratio. Glomerular hypertension and GBM hypertrophy evoked marked reductions in the clearance of cystatin C (Figure 1 B & Figure 3). Plotted in Figure 1 B are the simulated ratios of $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ in a normal glomerulus having a glomerular basement membrane thickness of 300 nm and an effective filtration pressure (EFP) of 10 mmHg *versus* a “diabetic” glomerulus having a glomerular basement membrane thickness of 900 nm and an effective filtration pressure (EFP) of 30 mmHg. According to the current model, the impact of differently sized solutes is heterogeneous. Shown in Figure 3 are simulated glomerular sieving coefficients vs. the Stokes-Einstein radii of the solute proteins for three different scenarios. The solid line represents a normal healthy subject having a glomerular basement

membrane thickness of ~300 nm and an effective filtration pressure (EFP) of 10 mmHg. Also plotted are experimentally measured sieving coefficients for β_2 -microglobulin²⁷ (black square) and myoglobin¹¹ (black triangle). The simulated sieving coefficient of cystatin C is also shown (black hexagon). The sieving coefficient for cystatin C is, under normal conditions ~0.84 corresponding to a glomerular clearance of ~5/6 of GFR, i.e. $Cl_{CC} \approx 100$ mL/min/1.73m² for a relative GFR of 120 mL/min. For the scenarios with a thicker glomerular filter (dashed and dotted line), glomerular hypertension is assumed necessary to maintain the same GFR and the EFP will increase linearly with the thickness of the barrier, thus for a 600 nm barrier (dashed line) the EFP is 20 mmHg. This thickening of the barrier will also double the diffusion distance for cystatin C, effectively lowering its fractional clearance to 0.74 ($Cl_{CC} \approx 89$ mL/min/1.73m²) for the 600 nm barrier and to 0.67 for the 900 nm barrier ($Cl_{CC} \approx 80$ mL/min/1.73m²). Assuming a constant production of cystatin C, these latter scenarios will cause the serum concentration of cystatin C (and other small proteins) to increase so that the estimated GFR using e.g. the CAPA equation²³ will be lower than GFR. This effect is shown in Table 2. By contrast, the sieving coefficient of a 3.05 nm protein (here exemplified by neutral horseradish peroxidase nHRP¹¹; solid star) will be practically unaltered by the thickening of the renal filter.

Theoretical effects of actual 'shrunk pores' in the glomerular filter

In Figure 4, the modeled sieving coefficients vs. SE-radius are plotted for scenarios with shrunk pores, 3.4 nm (dashed line) and 3.2 nm (dotted line). Expectedly, shrinking the pore size causes the sieving curve to shift to the left. As can be seen, pore shrinking has similar effects to thickening of the GFB for smaller proteins. However, by contrast, it has marked effects for larger solutes having radii close to the pore radius (< 3.7 nm). For the 3.05

nm protein (nHRP, star) the sieving coefficient will be reduced by a factor ~20 if the pores are shrunken to 3.2 nm. The effects of the different scenarios are demonstrated in Figure 5, where the ratio of the pathological vs. healthy scenarios in Figure 3 and 4 are plotted. Thus, an ideal solute size to detect GFB thickening would be approximately 2.5 nm whereas solutes exceeding 3.0 nm would be essentially unaffected under the current assumptions of an unchanged GFR, but the same effect will be present during conditions with a lower GFR. Actually, for slightly decreased GFRs, CrCl will typically overestimate the actual GFR contributing to SPS.

Discussion

We here provide theoretical modeling and clinical data suggesting that the diffusive clearance of middle-molecular species such as cystatin C is reduced in DKD to a degree corresponding with the increment in the thickness of the glomerular basal membrane. We demonstrate a linear relationship between the ratio $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ and basal membrane thickness. According to theory, during conditions of glomerular vascular wall thickening, there should be a measurable difference in the eGFR measured using cystatin C and the actual GFR (e.g. as measured by iohexol) under the assumption that their plasma concentrations are determined chiefly by glomerular filtration. In line with our present results, a decreased diffusional clearance of mid-sized molecules has been found in experimental and clinical studies of diabetic kidney disease ^{12, 32, 33}. There were however considerable variations in the $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ ratio in our data indicating that factors other than glomerular filtration may be involved. It is well-known that the steady-state plasma concentration of creatinine is affected by a number of other factors ³⁴ which limits its use as a reliable GFR-marker. Similarly, cystatin C concentrations are affected by conditions such as high-dose corticosteroid medication ³⁵. A limitation in the current study is therefore that it cannot be excluded that factors other than glomerular filtration affected the plasma levels of cystatin C and/or creatinine. A low muscle mass could give a higher $\text{eGFR}_{\text{creatinine}}$ and thus lower $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ ratio. Regarding the effect of muscle mass on shrunken pore syndrome we could not find a correlation between BMI and $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ ratio. It has been described increased levels of cystatin C after high-dose corticosteroids which would give a low $\text{eGFR}_{\text{cystatin C}}/\text{eGFR}_{\text{creatinine}}$ ratio. In our cohort only three patients with MCD were treated with at least 30 mg prednisolon at the time of biopsy and no patients with DKD, which rules out an effect of steroids on our results.

Recently the shrunken pore syndrome was reported which is characterized by a low ratio $eGFR_{cystatin\ C}/eGFR_{creatinine}$, and we wanted to study this ratio in correlation to the thickness of the basal membrane. However, the question of whether shrunken pore syndrome is the result of actual shrunken pores or vascular wall hypertrophy cannot be determined from the current data. Theoretically, shrinking of pores has more dramatic effects on the renal clearance of larger middle-molecules between 3.0 - 3.5 nm compared to small molecules, like creatinine and urea. Interestingly, many important plasma proteins, enzymes and peptide hormones are in this size range (e.g. cardiac Troponin T, TSH, AST, ALT and albumin) but many of them are catabolized in other tissues and regulated via other mechanisms making it unclear what effect shrunken pores would have on their plasma concentrations. It is well established that GFR is an important determinant of plasma cardiac troponin T (cTnT) levels^{36, 37}. According to our calculations, plasma cTnT levels should be several fold higher in a patient with shrunken pore syndrome (~20 times higher for the 3.2 nm pore size), if shrunken pore syndrome is caused by an actual "pore shrinkage".

The bi-selective nature of the GFB is well described in the literature³⁰. For the renal glomerular microcirculation, the first theoretical description was introduced by Deen et al in 1985²⁹ using a model consisting of two distinct pathways for solute transport. Thus far, the most "accurate" theoretical description of the GFB is similar to that of a highly size-selective mechanical cross-flow filter, meaning that most of the blood flow through the glomerular capillaries travels in a direction tangentially across the capillary wall rather than entering the renal filter. Also, the red blood cells travel through the capillary in a compressed "cell-by-cell fashion" and thus constantly comb the filter surface. Both of these mechanisms, tangential solvent flux and continuous combing of the endothelial glycocalyx by RBCs, may counteract clogging of the renal filter. However, inevitably, some solutes must enter the capillary wall

and, thus, must be dealt with via other mechanisms. Podocytes have been shown to exhibit endocytosis (and transcytosis) of albumin which will contribute to the clearance of albumin from the glomerular filter³⁸.

To understand why only solutes between 1.0 – 3.0 nm are affected by a thicker GFB one must first understand the concept of diffusion capacity, the proportionality coefficient in Fick's equation

$$J_s = PS \cdot \Delta c$$

Here PS is the diffusion capacity in mL/min, J_s is the diffusive solute flux in mmol/min and Δc is the concentration gradient (Plasma water concentration – Bowman's space concentration) in mmol/mL. From the equation above it can be seen that the diffusion capacity represents the maximal possible absolute diffusive clearance of a solute, being approached as the concentration on one side of the barrier is approaching zero.

Mathematically, PS is the product of the diffusion coefficient D and the effective surface area A of the membrane divided by the membrane thickness Δx (i.e. $PS = D \times A / \Delta x$), which means that PS will be reduced if the thickness, or diffusion length, Δx , is increased. Due to their small size, solutes like creatinine, urea, glucose *et cetera* have a great capacity to be transported via diffusion over the GFB since they have a very large diffusion capacity. Yet, diffusion is a process that requires a concentration gradient; and since small solutes < 1.0 nm are not sieved at all by the GFB $\Delta c = 0$ they will be transported entirely via convection and their clearance will equal GFR. For mid-sized solutes 1.0 – 3.0 nm there is a small but important concentration difference across the renal filter, leading to a considerable part of their clearance being due to diffusion due to the fact that the diffusion capacity is still very high (>> higher than GFR) for these solutes. With increasing solute sizes > 3.0 nm the

diffusion capacity rapidly drops to low values ($\ll$ lower than GFR), and the diffusive clearance becomes negligible.

Strengths

A validated registry for renal biopsy in which GFR was estimated from both creatinine and cystatin C is a strength of this study. The ultrastructural morphometry of the thickness of the GBM was evaluated by an experienced pathologist on enlarged electron micrographs as the arithmetic mean of 20 orthogonal intercepts across the GBM.

Limitations

A major limitation is the low number of patients in both groups. However, the differences between the two groups, regarding $eGFR_{\text{cystatin C}}/eGFR_{\text{creatinine}}$ ratio and GBM thickness, were statistically significant.

In conclusion DKD develops insidiously over several years, well before any clinical manifestations (e.g. declining GFR and microproteinuria) are evident, and once microproteinuria is present, structural lesions are often considerably advanced. Caramori *et al* analyzed 94 biopsies in normoalbuminuric patients, and found that GBM thickness was the only structural parameter that predicted progression to diabetic nephropathy. Our data show that basal membrane thickness is associated with the clearance of freely filtered molecules in relation to their molecular weight obvious from a reduced ratio $eGFR_{\text{cystatin C}}/eGFR_{\text{creatinine}}$.

In light of our current findings, further research should explore the possibility that plasma levels of mid-sized molecules like cystatin C could act as bio-markers for detecting

DKD, allowing early treatment. The ratio $eGFR_{\text{cystatin C}}/eGFR_{\text{creatinine}}$ may also be helpful in diagnosing other cases of CKD in early phases.

Author contributions

CAÖ and AC designed the study and collected data. CAÖ performed mathematical modeling. CAÖ and AC analyzed the data. CAÖ made the figures. ML analyzed kidney biopsies. CAÖ, AG and AC drafted the manuscript. All authors contributed to, and approved the final version of the manuscript.

Acknowledgements

We dedicate this work to the memory of Professor Bengt Rippe (Gothenburg, 1950 – Lund, 2016), whose seminal work on the theoretical basis of fluid and solute transport across glomerular capillaries is now well recognized. The engaging and enthusiast personality of Bengt Rippe inspired a whole generation of physician-scientists. This work was funded by the medical faculty of Lund-Malmö (ALF-grant), the Swedish Kidney Foundation, Njurstiftelsen, Skåne University Hospital Research Fund and the Research and Development Council of Region Skåne, Sweden.

Disclosures

All the authors declare no conflict of interest.

Supplemental Material

This article contains the following supplemental material

Supplemental File 1: STARD-checklist

References

1. Liyanage, T, Ninomiya, T, Jha, V, Neal, B, Patrice, HM, Okpechi, I, Zhao, MH, Lv, J, Garg, AX, Knight, J, Rodgers, A, Gallagher, M, Kotwal, S, Cass, A, Perkovic, V: Worldwide access to treatment for end-stage kidney disease: a systematic review. *Lancet*, 385: 1975-1982, 2015.
2. Soveri, I, Berg, UB, Björk, J, Elinder, C-G, Grubb, A, Mejare, I, Sterner, G, Bäck, S-E, Group, SGR: Measuring GFR: a systematic review. *American Journal of Kidney Diseases*, 64: 411-424, 2014.
3. Simonsen, O, Grubb, A, Thysell, H: The blood serum concentration of cystatin C (γ -trace) as a measure of the glomerular filtration rate. *Scandinavian journal of clinical and laboratory investigation*, 45: 97-101, 1985.
4. Shlipak, MG, Mattes, MD, Peralta, CA: Update on Cystatin C: Incorporation Into Clinical Practice. *American Journal of Kidney Diseases*, 62: 595-603, 2013.
5. Newman, DJ, Thakkar, H, Edwards, RG, Wilkie, M, White, T, Grubb, AO, Price, CP: Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. *Kidney international*, 47: 312-318, 1995.
6. Tangri, N, Inker, LA, Tighiouart, H, Sorensen, E, Menon, V, Beck, G, Shlipak, M, Coresh, J, Levey, AS, Sarnak, MJ: Filtration Markers May Have Prognostic Value Independent of Glomerular Filtration Rate. *Journal of the American Society of Nephrology*, 23: 351-359, 2012.
7. Smith, ER: Cystatin C - More than a filtration marker? *Atherosclerosis*, 230: 73-75, 2013.
8. Dharnidharka, VR, Kwon, C, Stevens, G: Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. *American Journal of Kidney Diseases*, 40: 221-226, 2002.

9. Dardashti, A, Nozohoor, S, Grubb, A, Bjursten, H: Shrunken Pore Syndrome is associated with a sharp rise in mortality in patients undergoing elective coronary artery bypass grafting. *Scand J Clin Lab Inv*, 76: 74-81, 2016.
10. Tenstad, O, Roald, AB, Grubb, A, Aukland, K: Renal handling of radiolabelled human cystatin C in the rat. *Scandinavian journal of clinical and laboratory investigation*, 56: 409-414, 1996.
11. Lund, U, Rippe, A, Venturoli, D, Tenstad, O, Grubb, A, Rippe, B: Glomerular filtration rate dependence of sieving of albumin and some neutral proteins in rat kidneys. *Am J Physiol-Renal*, 284: F1226-F1234, 2003.
12. Oberbauer, R, Nenov, V, Weidekamm, C, Haas, M, Szekeres, T, Mayer, G: Reduction in mean glomerular pore size coincides with the development of large shunt pores in patients with diabetic nephropathy. *Nephron Experimental Nephrology*, 9: 49-53, 2000.
13. Grubb, A: Shrunken pore syndrome-a common kidney disorder with high mortality. Diagnosis, prevalence, pathophysiology and treatment options. *Clinical Biochemistry*, 2020.
14. Åkesson, A, Lindström, V, Nyman, U, Jonsson, M, Abrahamson, M, Christensson, A, Björk, J, Grubb, A: Shrunken pore syndrome and mortality: a cohort study of patients with measured GFR and known comorbidities. *Scandinavian Journal of Clinical and Laboratory Investigation*: 1-12, 2020.
15. Grubb, A, Lindström, V, Jonsson, M, Bäck, S-E, Åhlund, T, Rippe, B, Christensson, A: Reduction in glomerular pore size is not restricted to pregnant women. Evidence for a new syndrome: 'Shrunken pore syndrome'. *Scandinavian journal of clinical and laboratory investigation*, 75: 333-340, 2015.

16. Rippe, B, Öberg, CM: Albumin Turnover in Peritoneal and Hemodialysis. *Seminars in dialysis*. Wiley Online Library, 2016 pp 458-462.
17. Norden, AG, Lapsley, M, Lee, PJ, Pusey, CD, Scheinman, SJ, Tam, FW, Thakker, RV, Unwin, RJ, Wrong, O: Glomerular protein sieving and implications for renal failure in Fanconi syndrome. *Kidney Int*, 60: 1885-1892, 2001.
18. Marshall, CB: Rethinking glomerular basement membrane thickening in diabetic nephropathy: adaptive or pathogenic? *Am J Physiol Renal Physiol*, 311: F831-F843, 2016.
19. Deen, WM, Robertson, CR, Brenner, BM: A model of glomerular ultrafiltration in the rat. *The American journal of physiology*, 223: 1178-1183, 1972.
20. Oken, DE: An analysis of glomerular dynamics in rat, dog, and man. *Kidney international*, 22: 136-145, 1982.
21. Navar, LG, Arendshorst, WJ, Pallone, TL, Inscho, EW, Imig, JD, Bell, PD: The renal microcirculation. *Comprehensive Physiology*, 2008.
22. Bossuyt, PM, Reitsma, JB, Bruns, DE, Gatsonis, CA, Glasziou, PP, Irwig, L, Lijmer, JG, Moher, D, Rennie, D, de Vet, HCW, Kressel, HY, Rifai, N, Golub, RM, Altman, DG, Hooft, L, A., KD, Cohen, JF: STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. *BMJ*, 351: h5527, 2015.
23. Grubb, A, Horio, M, Hansson, LO, Bjork, J, Nyman, U, Flodin, M, Larsson, A, Bokenkamp, A, Yasuda, Y, Blufpand, H, Lindstrom, V, Zegers, I, Althaus, H, Blirup-Jensen, S, Itoh, Y, Sjostrom, P, Nordin, G, Christensson, A, Klima, H, Sunde, K, Hjort-Christensen, P, Armbruster, D, Ferrero, C: Generation of a new cystatin C-based estimating equation for glomerular filtration rate by use of 7 assays standardized to the international calibrator. *Clin Chem*, 60: 974-986, 2014.

24. Nyman, U, Grubb, A, Larsson, A, Hansson, L-O, Flodin, M, Nordin, G, Lindström, V, Björk, J: The revised Lund-Malmö GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population. *Clinical Chemistry and Laboratory Medicine (CCLM)*, 52: 815-824, 2014.
25. Öberg, CM, Groszek, JJ, Roy, S, Fissell, WH, Rippe, B: A distributed solute model: an extended two-pore model with application to the glomerular sieving of Ficoll. *Am J Physiol-Renal*: ajprenal-00066, 2017.
26. Thomson, SC, Blantz, RC: Biophysical basis of glomerular filtration. In: *The Kidney: Physiology and Pathophysiology*. 4th ed. edited by R., A., S, H., Burlington, Elsevier/Academic Press, 2007, pp 565-588.
27. Edwards, A, Christensen, EI, Unwin, RJ, Norden, AG: Predicting the protein composition of human urine in normal and pathological states: quantitative description based on dent1 disease (CLCN5 mutation). *The Journal of Physiology*, 2020.
28. Dechadilok, P, Deen, WM: Hindrance factors for diffusion and convection in pores. *Ind Eng Chem Res*, 45: 6953-6959, 2006.
29. Deen, WM, Bridges, CR, Brenner, BM, Myers, BD: Heteroporous model of glomerular size selectivity: application to normal and nephrotic humans. *Am J Physiol*, 249: F374-389, 1985.
30. Öberg, CM, Rippe, B: A distributed two-pore model: theoretical implications and practical application to the glomerular sieving of Ficoll. *American journal of physiology Renal physiology*, 306: F844-854, 2014.
31. Blouch, K, Deen, WM, Fauvel, JP, Bialek, J, Derby, G, Myers, BD: Molecular configuration and glomerular size selectivity in healthy and nephrotic humans. *The American journal of physiology*, 273: F430-437, 1997.

32. Lubbad, L, Oberg, CM, Dhanasekaran, S, Nemmar, A, Hammad, F, Pathan, JY, Rippe, B, Bakoush, O: Reduced glomerular size selectivity in late streptozotocin-induced diabetes in rats: application of a distributed two-pore model. *Physiological reports*, 3, 2015.
33. Scandling, JD, Myers, BD: Glomerular Size-Selectivity and Microalbuminuria in Early Diabetic Glomerular-Disease. *Kidney international*, 41: 840-846, 1992.
34. Perrone, RD, Madias, NE, Levey, AS: Serum Creatinine as an Index of Renal-Function - New Insights into Old Concepts. *Clin Chem*, 38: 1933-1953, 1992.
35. Cimerman, N, Brguljan, PM, Krasovec, M, Suskovic, S, Kos, J: Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. *Clinica chimica acta; international journal of clinical chemistry*, 300: 83-95, 2000.
36. Tsutamoto, T, Kawahara, C, Yamaji, M, Nishiyama, K, Fujii, M, Yamamoto, T, Horie, M: Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure. *European journal of heart failure*, 11: 653-658, 2009.
37. Abbas, NA, John, RI, Webb, MC, Kempson, ME, Potter, AN, Price, CP, Vickery, S, Lamb, EJ: Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. *Clin Chem*, 51: 2059-2066, 2005.
38. Castrop, H, Schiessl, IM: Novel routes of albumin passage across the glomerular filtration barrier. *Acta Physiol (Oxf)*, 219: 544-553, 2017.

Table 1. Clinical GFR estimations

Parameter	DKD (n = 17)	MCD (n = 12)
Age, years	56 (43 – 65)	46 (30 – 54) †
eGFR _{crea} ^a mL min ⁻¹ 1.73m ⁻²	32 (21 – 38)	88 (48 – 97) ***
eGFR _{cysC} ^b mL min ⁻¹ 1.73m ⁻²	23 (14 – 27)	73 (46 – 96) ***
eGFR ^c , mL min ⁻¹ 1.73m ⁻²	25 (18 – 32)	82 (47 – 96) ***
GBM thickness, nm	747 (620 – 839)	376 (335 – 404) ***

Values are given as median (IQ range).

^a Calculated using the CAPA equation: $eGFR_{CAPA} = 130 \times \text{cystatin C}^{-1.069} \times \text{age}^{-0.117} - 7$ ²³.

^b Calculated using the LM rev equation ²³.

^c Average estimated GFR

† P=0.13

Table 2. Glomerular hypertension and hypertrophy in a human glomerulus model

Barrier thickness	300 nm	600 nm	900 nm
GFR, mL/min/1.73 m ²	120	120	120
Cystatin C, mg/L	0.70	0.79	0.88
eGFR _{CAPA} †	121	105	93
† eGFR _{CAPA} = 130 × cystatin C ^{-1.069} × age ^{-0.117} – 7			

Figure Legends

Figure 1

A: Estimated GFR from cystatin C and creatinine ratio in patients with a biopsy diagnosis of either diabetic kidney disease (DKD; n=17) or minimal change disease (MCD; n=12). B: Estimated GFR from cystatin C and creatinine in a theoretical model of the human glomerular filtration barrier. In silico simulations were performed either assuming a normal thickness of the glomerular basement membrane (GBM; 300 nm) or a hypertrophic GBM being 3 times thicker (900 nm). It was assumed that GFR remained constant as a result of tubulo-glomerular feedback, thus implying a three times higher effective filtration pressure across the glomerulus in the hypertrophic condition.

Figure 2

A: Estimated GFR from cystatin C and creatinine ($eGFR_{\text{cystatin C}}/eGFR_{\text{creatinine}}$) ratio versus glomerular basement membrane thickness as assessed via electron micrographs from kidney biopsies. B: Difference between modeled and measured $eGFR_{\text{cystatin C}}/eGFR_{\text{creatinine}}$ ratio as a function of glomerular basement membrane thickness.

Figure 3

Glomerular sieving coefficients vs. the Stokes-Einstein radii of the solute proteins for three different thicknesses of the glomerular basement membrane 300 nm (and an effective filtration pressure (EFP) of 10 mmHg), 600 nm (EFP 20 mmHg), 900 nm (EFP 30 mmHg). Also shown are experimentally measured sieving coefficients for β_2 -microglobulin¹⁷ (black square) and myoglobin¹¹ (black triangle). The sieving coefficient of a 3.05 nm protein

(neutral horseradish peroxidase nHRP¹¹; solid star) will be practically unaltered by the thickening of the renal filter.

Figure 4

Glomerular sieving coefficients vs. SE-radius are for scenarios with shrunken pores, 3.4 nm (dashed line) and 3.2 nm (dotted line) compared to normal (3.7 nm; solid line).

Figure 5

Pathological vs. healthy scenarios, either due to thickening of the glomerular filter (solid lines) to 600 nm or 900 nm, or shrinking of the functional pores (dashed lines) to 3.4 nm or 3.2 nm.

Clinical data

Human glomerulus model